Aim Immunotech INC S-1 registration statements

AIM ImmunoTech Inc. has filed an S-1 registration statement to allow for the resale of up to 13,077,089 shares of common stock by selling stockholders.

AIM ImmunoTech Inc. has filed an S-1 registration statement to allow for the resale of up to 31,287,933 shares of common stock by selling stockholders.

AIM ImmunoTech Inc. files an S-1/A for a rights offering to raise capital through the distribution of units comprising Series G Convertible Preferred Stock and Class G Common Stock Purchase Warrants to existing shareholders and warrant/option holders.

AIM ImmunoTech Inc. is conducting a non-transferable rights offering to raise up to $12 million for general corporate purposes, clinical trials, and debt repayment, while facing NYSE American listing non-compliance.

AIM ImmunoTech Inc. announced a non-transferable rights offering to raise up to $12 million through the sale of units comprising Series G Convertible Preferred Stock and warrants, while providing updates on its Ampligen clinical programs.

AIM ImmunoTech Inc. is conducting a non-transferable subscription rights offering to raise up to $12 million by selling units consisting of Series G Convertible Preferred Stock and Warrants.

AIM ImmunoTech Inc. is seeking to raise up to $10 million through a unit offering of common stock and warrants to address a negative stockholders' equity and regain compliance with NYSE American listing standards, following a recent reverse stock split and temporary delisting.

AIM ImmunoTech Inc. has filed an amended registration statement for a public offering of up to $10 million in units, seeking to raise capital while facing significant financial challenges including negative stockholders' equity and a risk of delisting from the NYSE American.

AIM ImmunoTech aims to raise up to $10 million through a unit offering to fund clinical programs, manufacturing, and legal expenses.

AIM ImmunoTech Inc. announces a proposed offering of up to 49,701,789 units, each containing common stock or a pre-funded warrant, and Class E and F warrants, aiming to raise approximately $10 million for working capital and clinical development.

AIM ImmunoTech launches a best efforts unit offering to raise capital for clinical trials, manufacturing, and legal expenses, while addressing NYSE American compliance.

AIM ImmunoTech has filed a registration statement for the resale of 9,306,072 shares of common stock issuable upon the exercise of warrants previously sold in a private placement.

AIM ImmunoTech has filed a registration statement for the resale of up to 11,281,916 shares of common stock issuable upon the exercise of warrants previously sold in a private placement.

AIM ImmunoTech intends to offer up to 9,975,000 shares of common stock through an equity line of credit with Atlas Sciences, LLC, potentially raising up to $15 million.